BRIGHT

• Improve understanding of tumour heterogeneity to better predict patient prognosis and response to treatment
• Identify and target mechanisms underlying treatment resistance in brain tumours
• Modify the interactions between tumour cells and the microenvironment in order to optimize new treatments such as immunotherapy.

• Integrated study of the heterogeneity of brain tumors (glioblastomas, IDH-mutated gliomas, brain lymphomas and rare tumors), combining multi-omic analyses (epigenetic, transcriptomic and histomic genetics) exploration of interactions with the tumor microenvironment, and development of innovative tools in advanced imaging and artificial intelligence (Carriers: Agusti Alentorn, Franck Bielle, Francesca Branzoli, Khê Hoang-Xuan).
• Characterization of mechanisms of resistance to chemotherapy and immunotherapy and development of new therapeutic strategies, particularly in glioblastoma, aimed at improving the prognosis of patients by using lines-like models derived from patients, xenografts, tumoroids and organoids (Carriers: Ahmed Idbaih, Isabelle Le Roux, Mehdi Touat, Maïté Verreault).
• The study of interactions between tumour cells and their microenvironment, particularly myeloid cells, and epigenomic modifications to identify predictive biomarkers of response to HDI inhibitors and characterize therapeutic synergies. (Sponsors: Marc Sanson, Michel Mallat, Luis J. Castro-Vega).

2025

• Kacimi S et al. Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma. J Clin Oncol . 2025 Jan 20;43(3):329-338.
• Nichelli L et al. Incorporation of Edited MRS into Clinical Practice May Improve Care of Patients with IDH-Mutant Glioma. AJNR Am J Neuroradiol. 2025 Jan 8;46(1):113-120. doi: 10.3174/ajnr.A8413.
• Hernández-Verdin I et al. Gut microbiome modulates the outcome in primary central nervous system lymphoma patients undergoing chemotherapy: An ancillary study from the BLOCAGE trial. Neuro Oncol. 2025 Sep 17;27(8):2090-2104.
• Morfouace M, Bielle Fet al. Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations. Eur J Cancer. 2025 Jun 18;223:115493. 

2024

• Carpentier A et al. Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial. Nat Commun. 2024 Feb 23;15(1):1650.

2023

• Di Stefano AL et al. In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of IDH-Mutant Diffuse Gliomas: The IDASPE Prospective Study. Neurology. 2023 Jan 3;100(1):e94-e106. doi: 10.1212/
• Salam R et al. Cellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma. Nat Commun. 2023 Jan 27;14(1):441. doi: 10.1038/s41467-023-36124-9.
• Hernández-Verdin I et al. Molecular and clinical diversity in primary central nervous system lymphoma. Ann Oncol. 2023 Feb;34(2):186-199.
• Lerond J, Mathon B, et al., Navarro V, Bielle F. Hippocampal and neocortical BRAF mutant non-expansive lesions in focal epilepsies. Neuropathol Appl Neurobiol. 2023 Oct;49(5):e12937.

2022

• Verreault M et al. Identification of growth hormone receptor as a relevant target for precision medicine in low-EGFR expressing glioblastoma. Clin Transl Med. 2022 Jul;12(7):e939.

2020

• Touat M et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 Apr;580(7804):517-523

2018

• Rosenberg S et al. A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas. Nat Commun. 2018 Jun 18;9(1):2371
• Labreche K et al. Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci. Acta Neuropathol. 2018 May;135(5):743-755.